Drug Safety

Soleno Faces Securities Class Action Over DCCR Safety as Investors Weigh May 5 Lead‑Plaintiff Deadline

Investors now confront a court test of claims that Soleno hid safety risks tied to its Prader‑Willi drug and overstated its launch outlook.